Evidence map›Paper›PMID 33355659›Full record

ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2022

Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib.

Harish Seethapathy, Meghan D Lee, Ian A Strohbehn, Orhan Efe, Nifasha Rusibamayila, Donald F Chute, Robert B Colvin, Ivy A Rosales, Riley M Fadden, Kerry L Reynolds and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Incidence and management of pyrexia syndrome in patients treated with dabrafenib and trametinib: a retrospective study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Harish SeethapathyDepartment of Medicine, Division of Nephrology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Meghan D LeeDepartment of Medicine, Division of Nephrology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Ian A StrohbehnDepartment of Medicine, Division of Nephrology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0003-2167-2896
Orhan EfeDepartment of Medicine, Division of Nephrology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Nifasha RusibamayilaDepartment of Medicine, Division of Nephrology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Donald F ChuteDepartment of Medicine, Division of Nephrology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Robert B ColvinDepartment of Pathology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Ivy A RosalesDepartment of Pathology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Riley M FaddenDepartment of Medicine, Division of Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Kerry L ReynoldsDepartment of Medicine, Division of Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Ryan J SullivanDepartment of Medicine, Division of Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Howard L KaufmanDepartment of Medicine, Division of Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Kenar D JhaveriDonald and Barbara Zucker School of Medicine at Hofstra/Northwell, Division of Kidney Diseases and Hypertension, Great Neck, NY, USA.
Meghan E SiseDepartment of Medicine, Division of Nephrology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Harvard University · USDonald & Barbara Zucker School of Medicine at Hofstra/Northwell · US

Funding

Effect of Hepatitis C Virus Eradication on Chronic Kidney Disease ProgressionK23DK117014 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI SISE, MEGHAN E. · 2018 to 2022
$865k
NIDDK NIH HHS K23 DK117014
6 · The paper itself

Abstract

backgroundOur objective was to characterize the incidence, risk factors and clinical features of acute kidney injury (AKI) in patients receiving dabrafenib and trametinib.

methodsWe performed a retrospective cohort study examining the kidney outcomes of patients in a large healthcare system who received dabrafenib/trametinib between 2010 and 2019. The primary outcome was AKI, defined as a 1.5-fold increase in serum creatinine from baseline within a 12-month study period. AKI severity and etiology was determined for each case by chart review. Logistic regression was used to evaluate baseline predictors of AKI.

resultsA total of 199 patients who received dabrafenib in our healthcare system from 2010 to 2019 were included in the analysis. Forty-two patients (21%) experienced AKI within 12 months; 10 patients (5% of the total cohort, 24% of AKI patients) experienced AKI occurring during a dabrafenib/trametinib-induced febrile syndrome characterized by fever, chills, gastrointestinal symptoms and elevated liver enzymes. Preexisting liver disease was the only significant predictor of AKI in the cohort. One patient had biopsy-proven granulomatous acute interstitial nephritis that resolved with corticosteroids.

conclusionsOncologists and nephrologists should be aware that AKI is common after dabrafenib/trametinib and a substantial number of cases occur in the setting of treatment-induced pyrexia.

Indexed as

Acute Kidney InjuryMelanomaAntineoplastic Combined Chemotherapy ProtocolsHumansImidazolesMutationOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonesRetrospective StudiesdabrafenibImidazolesOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinibacute kidney injuryBRAFMEKnephrotoxicity

Identifiers

PMID33355659
PMCPMC8875461
OpenAlexW3116580032

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.